Condition: KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.
This description comes directly from the study's public registry record.
Hongxia Han · +0518-81220121 · hongxia.han@hengrui.com
Always discuss trial participation with your own doctor first.
| Renji Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07232875